JP2026062640A5 - - Google Patents
Info
- Publication number
- JP2026062640A5 JP2026062640A5 JP2025205790A JP2025205790A JP2026062640A5 JP 2026062640 A5 JP2026062640 A5 JP 2026062640A5 JP 2025205790 A JP2025205790 A JP 2025205790A JP 2025205790 A JP2025205790 A JP 2025205790A JP 2026062640 A5 JP2026062640 A5 JP 2026062640A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg
- pharmaceutical composition
- patient
- regimen
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010113391.3 | 2020-02-24 | ||
| CN202010113391 | 2020-02-24 | ||
| CN202010174086.5 | 2020-03-13 | ||
| CN202010174086.5A CN113289002A (zh) | 2020-02-24 | 2020-03-13 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| PCT/CN2021/076772 WO2021169845A1 (zh) | 2020-02-24 | 2021-02-19 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| JP2022550720A JP7807815B2 (ja) | 2020-02-24 | 2021-02-19 | ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550720A Division JP7807815B2 (ja) | 2020-02-24 | 2021-02-19 | ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026062640A JP2026062640A (ja) | 2026-04-10 |
| JP2026062640A5 true JP2026062640A5 (https=) | 2026-04-22 |
Family
ID=77317937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550720A Active JP7807815B2 (ja) | 2020-02-24 | 2021-02-19 | ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 |
| JP2025205790A Pending JP2026062640A (ja) | 2020-02-24 | 2025-11-27 | ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550720A Active JP7807815B2 (ja) | 2020-02-24 | 2021-02-19 | ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230083149A1 (https=) |
| EP (1) | EP4115899A4 (https=) |
| JP (2) | JP7807815B2 (https=) |
| KR (1) | KR20220145870A (https=) |
| CN (2) | CN113289002A (https=) |
| AU (1) | AU2021225283A1 (https=) |
| CA (1) | CA3172439A1 (https=) |
| WO (1) | WO2021169845A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117797243A (zh) * | 2022-09-30 | 2024-04-02 | 上海泽生科技开发股份有限公司 | 神经调节蛋白及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| JP2000502682A (ja) | 1995-12-22 | 2000-03-07 | ローカルメッド インコーポレイテッド | 血管新生を促進する成長因子の局所的血管内デリバリー |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| JP2001519400A (ja) | 1997-10-14 | 2001-10-23 | ケンブリッジ ニューロサイエンス インク． | ニューレグリン使用を含む治療法 |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN104436167A (zh) * | 2010-06-12 | 2015-03-25 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP2964249A1 (en) * | 2013-03-06 | 2016-01-13 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| CN105561298A (zh) * | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN110835368A (zh) * | 2018-08-15 | 2020-02-25 | 上海泽生科技开发股份有限公司 | 神经调节蛋白多肽片段及其用途 |
-
2020
- 2020-03-13 CN CN202010174086.5A patent/CN113289002A/zh active Pending
-
2021
- 2021-02-19 US US17/799,252 patent/US20230083149A1/en active Pending
- 2021-02-19 AU AU2021225283A patent/AU2021225283A1/en active Pending
- 2021-02-19 JP JP2022550720A patent/JP7807815B2/ja active Active
- 2021-02-19 WO PCT/CN2021/076772 patent/WO2021169845A1/zh not_active Ceased
- 2021-02-19 CA CA3172439A patent/CA3172439A1/en active Pending
- 2021-02-19 EP EP21761756.2A patent/EP4115899A4/en active Pending
- 2021-02-19 CN CN202180015952.9A patent/CN115515620A/zh active Pending
- 2021-02-19 KR KR1020227032863A patent/KR20220145870A/ko active Pending
-
2025
- 2025-11-27 JP JP2025205790A patent/JP2026062640A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026062640A5 (https=) | ||
| CN102292346B (zh) | 肥胖的治疗 | |
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| IL277215B2 (en) | Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis | |
| AU2010220800B2 (en) | Method for preventing and treating hyperpermeability | |
| CN113072623B (zh) | 一种靶向SARS-CoV-2 N蛋白的干扰肽的制备方法及应用 | |
| JP2019031567A5 (https=) | ||
| WO2003079979A3 (en) | Method for treating congestive heart failure | |
| RU2014141514A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| JPWO2019156137A5 (https=) | ||
| JPH10509428A (ja) | 活性依存性神経栄養因子の神経栄養ペプチド | |
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| RU97107853A (ru) | Пептидная специфичность антител к мвр (миелиновому основному белку), содержащая его фармацевтическая композиция и способ лечения рассеянного склероза | |
| JP2025069284A5 (https=) | ||
| NO330954B1 (no) | Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose. | |
| JP2021523138A5 (https=) | ||
| JPH0232023A (ja) | パーキンソン症候群の治療用薬剤 | |
| JP5647609B2 (ja) | 経粘膜吸収性を付与したモチリン類似ペプチド化合物 | |
| US20230181697A1 (en) | Use of Surfactant Protein D to Treat Viral Infections | |
| JP2025060703A5 (https=) | ||
| JPS60184011A (ja) | 免疫調節剤 | |
| JP2025532676A5 (https=) | ||
| JP2002501487A (ja) | トリの抗体の使用法 | |
| CN108721314A (zh) | 化合物epz5676及其相关抑制剂在制备防治肺纤维化疾病药物中的用途 | |
| JPH06220090A (ja) | ポリペプチド |